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Background: AICAR is a potent anti-proliferative compound, but the basis of its cytotoxicity is poorly understood.
Results: AICAR affects NTP homeostasis in a carbon source-dependent way, in both yeast and human cells.
Conclusion: AICAR balance with nucleotides triphosphate is critical for its in vivo effects.
Significance: AICAR is significantly more cytotoxic on glucose and thus potentially targets cells prone to Warburg effect.
5-Aminoimidazole-4-carboxamide-1--D-ribofuranoside mo-
nophosphate (AICAR) is a natural metabolite with potent anti-
proliferative and low energy mimetic properties. At high con-
centration, AICAR is toxic for yeast and mammalian cells, but
the molecular basis of this toxicity is poorly understood. Here,
we report the identification of yeast purine salvage pathway
mutants that are synthetically lethal with AICAR accumulation.
Genetic suppression revealed that this synthetic lethality is in
part due to low expression of adenine phosphoribosyl transfer-
ase under high AICAR conditions. In addition, metabolite pro-
filing points to the AICAR/NTP balance as crucial for optimal
utilization of glucose as a carbon source. Indeed, we found that
AICAR toxicity in yeast and human cells is alleviated when glu-
cose is replaced by an alternative carbon source. Together, our
metabolic analyses unveil the AICAR/NTP balance as a major
factor of AICAR antiproliferative effects.
Purine nucleotides are key metabolites that are efficiently
interconverted resulting in fine-tuned balances between ade-
nylic and guanylic derivatives but also between mono-, di-, and
triphosphate species. In particular, the AMP to ATP ratio is a
majormetabolic signal informing the cell about its energy state.
When energy is required, ATP is consumed, and the resulting
ADP is used to replenish the ATP pool in part via the adenylate
kinase reaction that generates AMP and ATP from two mole-
cules of ADP. This reaction does not require exogenous energy
and can thus rapidly refill the ATP pool upon demand. How-
ever, this reaction is limited by the size of the AXP pool and
rapidly leads to ADP depletion and AMP accumulation.
Increased AMP concentration is perceived as a low energy sig-
nal and contributes to redirect the metabolism to catabolism
(energy providing reactions) notably via activation of the AMP-
kinase (AMPK).4 Metabolic transitions can therefore be exper-
imentally triggered by modifying the AMP/ATP ratio. How-
ever, AMP accumulation is difficult to control experimentally,
and an AMP mimic molecule named AICAR (Fig. 1A), which
can be provided as a riboside precursor form (AICAr; Fig. 1A) in
the growth medium, is often used as low energy mimetic.
AICAR clearly activates AMPK in vitro and in vivo but also
shows many effects that are not AMPK-dependent (1, 2).
Whether these effects are the result of AMP mimicry or not is
unknown. The yeast AMPK ortholog Snf1 is activated by ADP
rather than AMP (3), and consistently the yeast AICAR tran-
scriptional signature did not include genes described as
strongly regulated by Snf1p (4). Yeast therefore is a good exper-
imental system to study the effects of AICAR that are AMPK-
independent. Identification of AMPK-independent targets of
AICAR is crucial because it was recently established that the
highly promising antiproliferative properties of AICAR are
largely AMPK-independent (5, 6). Importantly, AICAR cyto-
toxic effects were higher on trisomic mouse embryonic fibro-
blasts than on their euploid counterpart (7). This property
makes AICAR a promising anti-tumor molecule because most
solid tumor cells are aneuploid, i.e. have an incorrect number of
chromosomes.
As for mammalian cells, AICAR can be cytotoxic for yeast
cells (8). Understanding the molecular basis of AICAR toxicity
in yeast can thus give important clues on its effects in other
eukaryotic cells. However, it should be stressed that, by oppo-
sition to mammalian cells, simple addition of AICAr to the
growth medium does not result in AICAR monophosphate
accumulation in yeast unless the ADE16 ADE17 genes, encod-
ing AICAR transformylase IMP-cyclohydrolase, are mutated
(Fig. 1B) (5). This most probably reflects the fact that yeast
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AICAR transformylase IMP-cyclohydrolase very efficiently
metabolizes AICAR in vivo as discussed in Ref. 5. Thus, studies
of AICAR effects in yeast necessitate adequate genetic back-
grounds affecting synthesis and/or utilization of AICAR. We
have previously shown that AICAR can be detoxified in its ribo-
side form (AICAr) in an adenosine kinasemutant (ado1) unable
to resynthesize AICAR fromAICAr (9) (Fig. 1B). We also iden-
tified a mutant form of the phosphatase Pho13, named
Pho13-1, which can detoxify succinyl-AICAR to succinyl-
AICAR riboside and thereby diminish intracellular AICAR
concentration (9) (Fig. 1B). Together, these results established
that the riboside forms of AICAR and succinyl-AICAR are not
toxic for yeast cells, a situation highly similar to what happens
in mammalian cells where the vast majority of AICAR effects
are abolished by adenosine kinase inhibitors (1). Thus, for both
yeast and mammalian cells, it was concluded that AICAr ribo-
side had to be metabolized to the monophosphate form to
become active and cytotoxic. Transcriptomic analyses in yeast
(4, 9) did not give any obvious key for AICAR toxicity, and thus
themolecularmechanisms are still to be uncovered. To address
this question, we took advantage of yeast genetics to isolate
mutants unable to grow under conditions where AICAR accu-
mulates. Here, we describe such yeast mutants and connect
their AICAR sensitivity to their metabolite profile. Our results
point to the AICAR/NTP balance as a crucial feature of AICAR
toxicity. Importantly, we established that AICAR toxicity is
tightly linked to growth on glucose as a carbon source and can
be largely alleviated by alternative carbon sources both in yeast
and in mammalian cells. This glucose-specific toxicity of
AICAR could potently contribute to its antitumor properties
because most cancer cells exclusively rely on glucose metabo-
lism for energy production.
Experimental Procedures
Yeast Media, Strains, and Plasmids—SD is a synthetic mini-
mal medium containing 0.5% ammonium sulfate, 0.17% yeast
nitrogen base (Difco), 2% glucose. SDcasaW is SDmedium sup-
plemented with 0.2% casamino acids (Difco) and tryptophan
(0.2mM).When indicated, adenine (0.3mM), guanosine (1mM),
hypoxanthine (0.3 mM), inosine (1 mM), and/or uracil (0.3 mM)
was added in SDcasaW medium, resulting in media named
SDcasaWA ( adenine), SDcasaWHypox ( hypoxanthine),
SDcasaWAU ( adenine  uracil), and SDcasaWUHypox (
hypoxanthine  uracil). Synthetic medium containing differ-
ent carbon source correspond to SD medium in which glucose
has been replaced by 2% of the indicated carbon source. SC
medium was prepared as described by Sherman et al. (10). SC
complete medium is SC medium supplemented with adenine
(0.3mM), uracil (0.3 mM), histidine (0.06mM), leucine (0.4mM),
lysine (0.06 mM), and tryptophan (0.2 mM). YPD medium is a
complete medium containing 1% yeast extract, 2% bactopep-
tone, and 2% glucose. Yeast strains (Table 1) belong to, or are
derived from, a set of disrupted strains isogenic to BY4741 or
BY4742 purchased from Euroscarf. Multimutant strains were
obtained by crossing, sporulation, and micromanipulation of
meiosis progeny. Plasmids allowing overexpression of AAH1
(p2088), ADE12 (p1032), ADE13 (p1971), ADK1 (p2151 (11)),
AMD1 (p2479 (12)), APT1 (p2091 (12)), HPT1 (p2149 (13)),
GUA1 (p2141), GUK1 (p1814), IMD2 (p2093), IMD3 (p2100),
IMD4 (p2102), and PHO13-1 (p4291 (9)) were obtained by
cloning in the pCM189 vector (tetProm,CEN,URA3) (14). Clon-
ing details for the unpublished plasmids are available upon
request.
Isolation of AICAR-sensitive Mutants—To obtain AICAR-
sensitive mutants, an ade16 ade17 strain (Y4999), transformed
with a plasmid expressing the PHO13-1 dominant allele under
the control of a tetracycline-repressible promoter, was plated
on SDcasaWA medium, mutagenized with UV-light for 40 s,
and then grown for 48 h at 30 °C. The resulting cloneswere then
transferred by replica-plating on the same medium alone or
medium containing doxycycline (10 mg/liter) to repress
PHO13-1 expression. AICAR-sensitive mutants were isolated
as clones unable to grow in the presence of doxycycline but
growing in the absence of the antibiotic.
Metabolite Extraction and Separation by Liquid
Chromatography—Extraction of yeast and mammalian cells
metabolites was performed as described (5), and metabolite
separation was performed on an ICS3000 chromatography sta-
tion (Dionex, Sunnyvale, CA) using a carbopac PA1 column
FIGURE 1. Schematic representation of purine and histidine pathways in
yeast. A, chemical structures of AICAR, AMP, and their riboside derivatives. B,
only the enzymes mentioned in the text are indicated. Ade, adenine; Ado,
adenosine; Guo, guanosine; Hypox, hypoxanthine; Ino, inosine; PM, plasma
membrane; PRPP, 5-phosphoribosyl-1-pyrophosphate; SAICAr, succinyl-
AICAr; SAICAR, succinyl-AICAR; S-AMP, succinyl-AMP.
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(250 2mm; Dionex) with the 50–800mM acetate gradient in
50 mM NaOH described in Ref. 15. Peaks were identified by
their retention time, as well as by co-injection with standards
and/or their UV spectrum signature.
Mammalian Cells—HeLa cells (ATCC, CCL-2) were propa-
gated in DMEM, 4.5 g/liter glucose, 10% FCS, L-glutamine, and
penicillin/streptomycin. Cells were then trypsinized and
washed twice by centrifugation in glucose-free DMEM (Gibco
Life Technologies catalog no. 11966-025) containing 10% dia-
lyzed FCS and 1 mM pyruvate. They were then seeded at the
density of 30,000 cells/cm2 in culture dishes that have been
precoated for 2 h with 5 g/ml fibronectin (Sigma catalog no.
F4759) in PBS. The growth medium consisted of DMEMwith-
out glucose supplemented either with 5 mM glucose or 5 mM
galactose and containing 10% dialyzed FCS, 1 mM pyruvate, 5
g/ml insulin, 10 ng/ml EGF, 2 ng/ml FGF-2, and penicillin/
streptomycin. After 24 h, AICAr was added to the culture
medium, and the cells were further allowed to grow for 48 h.
AICAr toxicity was determined by counting cells with a Multi-
sizer 4 Coulter counter (Beckman).
Enzymatic Activities—For enzymatic activities, all measure-
ments were done in initial rate conditions that were stable for at
least 3 min at 30 °C for all enzymes tested. A potential effect of
AICAR on enzymatic activities was tested by preincubating or
not the protein extracts with AICAR (1 mM) for 2 min before
substrate addition. Finally, all enzymatic reactions were
stopped by boiling (3 min at 80 °C) a 100-l aliquot of the reac-
tion mix in 900 l of ethanol/10 mM Hepes, pH 7 (4/1, v/v).
Quantification of the reaction product(s) was done by liquid
chromatography in the conditions described for intracellular
metabolites determination. AMP deaminase enzymatic activity
was measured by a method adapted from (16). Briefly, a total
yeast protein extract was obtained from adk1 amd1 mutant
cells (Y3578) overexpressing (p2479) or not (pCM189) AMD1
and grown in SDcasaWA medium (100 ml, 5  107 cells/ml).
After harvesting, cells were resuspended in 500 l of buffer A
(50 mM triethanolamine, pH 7, 0.1 M KCl, and 100 M dithio-
threitol) and were disrupted by vortexing with glass beads (1
min, three times). The extract was then dialyzed twice against 2
liters of buffer A containing 10% (m/v) glycerol. Enzymatic
activity was measured in 500 l of buffer A containing AMP
(100M), ATP (100M), and the protein extract (250g, added
at time 0). AMP deaminase specific activity corresponds to
nmol IMP synthetized/min/mg of protein. No IMP synthesis
was detected in a protein extract obtained from the strain con-
taining the pCM189 empty vector. Adenine phosphoribosyl
transferase activity was determined using a total protein extract
from an aah1 amd1 mutant strain (Y2080) containing a plas-
mid allowing overexpression of APT1 (p2091), as described in
Ref. 17 but with modifications. Yeast cells grown in SDcasaW
medium were harvested (100 ml; 5  107 cells/ml) and dis-
rupted in 500 l of 50 mM Tris/HCl, pH 7.5, containing 5 mM
MgCl2, 20mMKCl, and 10% glycerol (buffer B). The suspension
was then centrifuged for 1 h at 21,000  g and 4 °C, and the
supernatantwas dialyzed twice against 2 liters of buffer B. Enzy-
matic activity was measured in 500 l of 50 mM Tris/HCl, pH
7.4, containing 5 mMMgCl2, 0.5 mg/ml BSA, 100 M phospho-
ribosyl pyrophosphate, 10, 50 or 100 M adenine, 0 or 1 mM
AICAR, and 12g of protein extract (added at time 0). Adenine
phosphoribosyl transferase specific activitywas defined as nmol
of AMP synthetized/min/mg of protein. No AMP synthe-
sis was detected in the absence of phosphoribosyl pyrophos-
phate. Adenylate kinase (Adk) activity was measured on Sac-
charomyces cerevisiae purified protein (Merck Millipore
TABLE 1
List of yeast strains used in this study
Strain name Genotype
BY4741 MATa his31 leu20 met150 ura30
BY4742 MAT his31 leu20 lys20 ura30
Y178 MAT his31 leu20 ura30
Y1095 MAT ade16::kanMX4 ade17::kanMX4 his31 leu20 ura30
Y1127 MATa hpt1::KanMX4 his31 leu20 met150 ura30
Y1759 MAT apt1::kanMX4 his31 leu20 ura30
Y2080 MATa aah1::KanMX4 amd1::KanMX4 his31 leu20 met150 ura30
Y2340 MATa aah1::kanMX4 ade8::kanMX4 his31 leu2 ura30
Y2950 MAT ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y3578 MAT adk1::kanMX4 amd1::kanMX4 his31 leu20 ura30
Y4479 MAT his31::HIS3-LEU2 leu20 ura30
Y4499 MATa ade16::kanMX4 ade17::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y5864 MATa hpt1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y5868 MAT hpt1::kanMX4 ade16::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y5870 MAT ade16::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y5873 MAT hpt1::kanMX4 ade17::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y5876 MAT ade17::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y6750 MATa aah1::kanMX4 his31 leu2 ra30
Y6986 MAT ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y7205 MAT aah1–308 ade16::kanMX4 ade17::kanMX4 his31::HIS3-LEU2 leu20 ura30 [tet-PHO13–1]
Y7314 MAT pdc2 (L234S) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y7320 MAT ade13 (G166S) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y7321 MAT thi3 (S402F)ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y8480 MATa ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y8793 MATa ade16::kanMX4 ade17::kanMX4 aah1::kanMX4 his31 leu20 ura30
Y8845 MAT thi80 (L90P) ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y9303 MAT aah1–308 ade16::kanMX4 ade17::kanMX4 his31::HIS3-LEU2 leu20 ura30
Y9798 MAT aah1::kanMX4 ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 his31 leu20 ura30
Y10314 MATa APT1-GFP-HIS3 his31 leu20 ura30 met150
Y10351 MATa ade16::kanMX4 ade17::kanMX4 APT1-GFP-HIS3 his31 leu20 ura30 met150
Y10399 MATa ade16::kanMX4 ade17::kanMX4 ade8::kanMX4 his1::kanMX4 kcs1:: kanMX4 his31 leu20 ura30
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catalog no. 474951) with a method derived from Ref. 18. The
reaction mixture (500 l) contained 100 mM Tris/HCl, pH 7.5,
0.1 M KCl, 5 mM MgCl2, 2 mM ADP, and 10 ng of purified Adk.
Specific activity was defined as the amount of ATP synthetized/
min/mg of purified protein.
Miscellaneous Methods—Yeast growth drop test were per-
formed as described in Ref. 12.
Results
Mutations in the AAH1 Gene Are Synthetically Lethal with
ade16 ade17 Mutations Resulting in AICAR Accumulation in
Vivo—To isolate mutants which are affected by AICAR accu-
mulation, we started from an ade16 ade17 double mutant that
constitutively accumulates AICAR ( 1mM comparedwith1
M in the wild-type strain (4)). In this double mutant strain, we
introduced a plasmid carrying the PHO13-1 gene under control
of a doxycycline repressible promoter. When expressed,
PHO13-1 decreases AICAR intracellular concentration (9).We
then isolated mutants that grew when PHO13-1 was expressed
(low intracellular AICAR) but were unable to grow in the pres-
ence of doxycycline (high intracellular AICAR). One of these
AICAR-sensitive mutants (Fig. 2A) was further studied. This
mutant showed an atypical metabolite profile characterized by
the massive intracellular accumulation of adenine, S-adenosyl-
methionine (AdoMet) and S-adenosylhomocysteine (SAH)
(Fig. 2B). The intracellular adenine accumulation was particu-
larly intriguing because this metabolite is usually hardly detect-
able,most probably as a result of its active utilization by adenine
deaminase (Aah1) and adenine phosphoribosyltransferase
(Apt1) (Fig. 1B). Adenine accumulation suggested thatAPT1 or
AAH1 could be affected in this mutant strain. Metabolite pro-
filing of apt1 and aah1 single knock-out mutants in the same
conditions revealed that only the aah1 mutant accumulates
high levels of adenine, AdoMet, and SAH (Fig. 2C, red lines).
Together, these results suggested that AAH1 could be the
mutated gene resulting in the synthetic lethality when com-
bined with the ade16 ade17mutations. Accordingly, sequenc-
ing of the AAH1 locus in this mutant revealed a stop codon at
FIGURE 2. AICAR toxicity is strongly increased in an adenine deaminase mutant using adenine as an external purine source. A, the AICAR-sensitive
mutant (Y7205) and the cognate reference strain (Y4499), both containing the Tet-OFF PHO13-1 expression plasmid (P4291), were grown overnight, serial
diluted, and spotted on SDcasaWAmediumwith or without doxycycline (Dox, 10 mg/l). B, strains from Fig. 2A (wild type, blue line; mutant, red line) were kept
in the exponential phase in SDcasaWA medium for 24 h and were then incubated with doxycycline (10 mg/liter) for 4 h prior to metabolite extraction and
separation. Asterisks indicate unidentified peaks found in the control strain that do not correspond to SAH. C, metabolite content was determined from wild
type (WT, Y178, blue line), aah1 (Y6750, red line), and apt1 (Y1759, green line) cells grown in SDcasaWAUmedium.D, the ade16 ade17 (AAH1, Y4499) and ade16
ade17 aah1-308 (aah1-308, Y9303) strains were grown overnight, serial diluted, and spotted on SDcasaWmedium containing either adenine or hypoxanthine
as an extracellular purine source. E, plasmids expressing (P2088) or not (control, pCM189) the AAH1 gene were transformed in the ade16 ade17 aah1-308
(aah1-308, Y9303) strain, and transformants were serial diluted and spotted on SDcasaW medium containing either adenine or hypoxanthine. F, the ade16
ade17 aah1 (Y8793) and ade8 aah1 (Y2340) strains were transformed with either the tet-PHO13-1 expression plasmid (P4291) or the pCM189 empty vector
(Control). Transformants were grown overnight, serial diluted, and spotted on SDcasaW medium supplemented with either adenine or hypoxanthine, as an
external purine source.G, mutant cells (ade16 ade17 ade8 his1 (Y2950); aah1 ade16 ade17 ade8 his1 (Y9798)) were grown overnight, serial diluted, and spotted
on SDcasaWAUmedium with or without external AICAr (5 mM). In A and D–G, the plates were imaged after 2 days at 30 °C.
Metabolic Basis of AICAR Toxicity
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position 308, resulting in a protein lacking the 39 C-terminal
residues. As expected, the mutant could grow in the absence of
the tet-PHO13-1 plasmid on hypoxanthine (Fig. 2D), a purine
source that bypasses the requirement for Aah1 (Fig. 1B), and
the synthetic lethality of the mutant on adenine medium was
complemented by the AAH1 gene carried on a plasmid (Fig.
2E). Finally, a reconstituted ade16 ade17 aah1 triple knock-out
mutant was unable to grow on adenine but grew perfectly well
on hypoxanthine (Fig. 2F), just as the original mutant from the
screen (Fig. 2D). As expected, accumulation of adenine, SAH,
and SAM was resumed in the reconstituted mutant (data not
shown). In addition, we observed that thismutant hadATP and
GTP pools lower by 30 and 60%, respectively (see next section).
We conclude thatade16 ade17 andaah1 are synthetically lethal
specifically on adenine-containing medium.
Importantly, this synthetic lethality of ade16 ade17 aah1 on
adeninewas indeed caused byAICAR accumulation because an
ade8 aah1 mutant showed no growth impairment, and the
overexpression of PHO13-1 restored growth of the triple ade16
ade17 aah1mutant (Fig. 2F). Finally, an aah1 ade16 ade17 ade8
his1mutant, unable to produce endogenous AICAR, grew per-
fectly well on adenine unless AICAr riboside was added to the
growth medium (Fig. 2G). Importantly, the ade16 ade17 ade8
his1 strain carrying the wild-type AAH1 allele was able to grow
in the presence of AICAr (Fig. 2G). We conclude that AICAR
accumulation enables proliferation when Aah1 is not
functional.
AICAR Affects ATP and GTP Intracellular Concentration—
The low ATP and GTP pools, found in the aah1 ade16 ade17
mutant, suggested that AICAR affected the purine interconver-
sion pathway. Because AICAR can act as an AMP mimetic on
AMPK, we reasoned that it could affect enzymes responsible
for synthesis (Apt1) or consumption (Adk1, Amd1) of AMP
(Fig. 1B). However, in vitro enzymatic assays showed no major
effect of AICAR on Apt1, Adk1, and Amd1 specific activities
(Fig. 3A). Although Apt1 enzymatic activity was not affected by
AICAR in vitro, we found that APT1 overexpression robustly
suppressed the aah1 ade16 ade17 lethality on adenine (Fig. 3B).
Importantly, none of the other purine salvage pathway genes
could allow growth on adenine when overexpressed (Fig. 3B).
We next attempted to understand the basis of AICAR cyto-
toxicity by analyzing the metabolite profiles of both an ade16
ade17 aah1 triple mutant and an aah1 single mutant grown in
various conditions. Among the eight combinations tested, a
strong growth defect was only observed in the triple ade16
ade17 aah1mutant grown on adenine containing medium and
not overexpressingAPT1 (conditionmarked by an arrow in Fig.
4A). Themetabolite profiling first showed that accumulation of
adenine, AdoMet, and SAH is unlikely to cause the growth
defect, because levels of these metabolites were similar in the
aah1 and aah1 ade16 ade17 strains (Fig. 4, B–D), which are
respectively able and unable to grow in the presence of adenine
(Fig. 4A). Second, we observed that the ATP and GTP intracel-
lular concentrations were lowered in the ade16 ade17 aah1
strain grown on adenine (Fig. 4, E and F). This result suggested
that, in this strain, synthesis of AMP from adenine by Apt1 was
not sufficient to satisfy cellular needs forGTP andATP. Indeed,
overexpression of Apt1 restored higher levels of both ATP and
GTP (Fig. 4, E and F) and allowed robust growth in the presence
of adenine (Fig. 4A). In good agreement with a role of both ATP
andGTPpools inAICAR sensitivity, overexpression of Adk1 or
Hpt1 that only partially restored the ATP and GTP pools,
respectively (Fig. 5, A and B), did not allow growth (Fig. 3B).
Consistently, the growth defect of the mutant was much more
efficiently rescued by inosine that can refuel the pathway for
both ATP and GTP than by guanosine that only contributes to
GTP synthesis (Figs. 1B and 5C). This effect on nucleotide
triphosphate appears limited to purine nucleotides because
UTP levels were not affected by the purine source or by over-
expression of Apt1 (Fig. 4G). Finally and most importantly,
overexpression of APT1 significantly lowered the intracellular
AICAR content (Fig. 4H). Thus, in the AICAR-sensitive condi-
tion, AICAR is overaccumulated, whereas purine nucleotide
triphosphate levels are lowered.
Mutations in the HPT1 and ADE13 Genes Are Synthetically
Lethal with AICAR Accumulation—We then asked whether
this effect was Aah1-specific or whether blocking adenine uti-
lization downstream of Aah1 would also result in AICAR-de-
pendent lethality. We therefore mated a hpt1mutant that can-
not transform hypoxanthine into IMP (Fig. 1B) with an ade16
FIGURE 3. AICAR does not affect enzymatic activities of AMP-metaboliz-
ing enzymes A, adenine phosphoribosyl transferase (Aprt), Adk, and AMP
deaminase (Ampd) enzymatic activities were determined as described under
“Experimental Procedures.” For each enzyme, specific activities were deter-
mined in the presence or the absence of AICAR. B, the ade16 ade17 aah1
(Y8793) strainwas transformedwith plasmids allowing overexpression of the
indicated genes or the pCM189 empty vector (none). Transformants were
grown overnight, serial diluted, and spotted on SDcasaW medium supple-
mented with either adenine or hypoxanthine as an external purine source.
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ade17 double mutant accumulating AICAR. The tetrads
obtained from the resulting diploid were dissected on an ade-
nine containingmedium. Strikingly, among 14 tetrads, no triple
ade16 ade17 hpt1 mutant was recovered (Fig. 6A and not
shown).We conclude that hpt1 is synthetically lethal in combi-
nation with ade16 ade17. Importantly, the knock-out of hpt1 is
not synthetically lethal with other mutations in the de novo
pathway such as ade2 (13, 19). To circumvent the ade16 ade17
hpt1 synthetically lethality, we used an ade17 hpt1 double
mutant that is viable but showed a growth defect (Fig. 6A,
underlined). Of note, Ade17 is the AICAR transformylase IMP-
cyclohydrolase isoform that contributes more than 90% of the
FIGURE 4. Impairment of growth and metabolite content of the ade16 ade17 aah1 mutant is suppressed by APT1 overexpression. A, strains (aah1:
Y6750; ade16 ade17 aah1: Y8793) were transformed with the APT1 expressing plasmid (P2091) or the pCM189 empty vector (control). Transformants were
grown overnight, serial diluted, and spotted on SDcasaW medium supplemented by either adenine or hypoxanthine. B–H, transformants from Fig. 4A were
kept in exponential growth for 24 h in SDcasaWmedium supplemented with hypoxanthine, harvested by centrifugation, resuspended in SDcasaWmedium
supplementedwith either adenine or hypoxanthine, and grown for 4 h at 30 °C prior tometabolic extraction and separation. Quantificationswere determined
from at least three independent metabolite extractions for each condition. Error bars indicate variations to the mean. In all panels, the no growth condition is
highlighted by the arrowhead. Metabolite content of the ade16 ade17 aah1mutant strain containing the empty vector and grown in hypoxanthine medium
was used as the reference and was set at 1.
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enzymatic activity (20). This growth impairment was further
enhanced when AICAR production was stimulated by growth
in the absence of histidine (Fig. 6B) (9). Importantly, overex-
pression of APT1 suppressed the growth impairment of the
hpt1 ade17mutant in the absence of histidine (Fig. 6C). Metab-
olite profiling of the ade17 hpt1mutant revealed that this dou-
ble mutant, grown in the absence of histidine, accumulated a
significant amount of AICAR and that overexpression of APT1
strongly reduced this AICAR accumulation (Fig. 6D). Impor-
tantly, in the ade17 hpt1mutant, overexpression of APT1 also
increased ATP and GTP levels, whereas it had little or no effect
on UTP (Fig. 6D). Together, our results establish that accumu-
lation of AICAR is highly toxic when yeast cells are unable to
synthesize purine de novo and to utilize hypoxanthine.
This prompted us to search for mutants unable to use hypo-
xanthine as a purine source in our collection ofAICAr-sensitive
mutants (5). This was indeed the case for the ahs15mutant (Fig.
6E). Metabolite profiling of ahs15 revealed massive accumula-
tion of succinyl-AMP (Fig. 6F), the substrate of Ade13, the
adenylosuccinate lyase (Fig. 1B). Accordingly, both hypoxan-
thine utilization defect and AICAr sensitivity were fully com-
plemented by the ADE13 gene carried on a plasmid (Fig. 6E).
Furthermore, AICAr sensitivity co-segregated with the inca-
pacity to use hypoxanthine in 10 tetrads (not shown). Sequenc-
ing of the ADE13 locus in the ahs15 mutant revealed a single
mutation resulting in a glycine to serine substitution at position
166 in the protein. This mutation co-segregated with AICAr
sensitivity and hypoxanthine auxotrophy in all 10 tetrads (not
shown). We conclude that ahs15 is allelic to ADE13. Finally,
metabolite profiling of the ahs15 mutant revealed that this
mutant had higher levels of AICAR and lower levels of purine
nucleotide triphosphate (Fig. 6F). Thus, as for the aah1mutant,
AICAr sensitivity in the hpt1 and ade13 mutants is associated
to high AICAR and low ATP and GTP levels.
We propose that ATP and AICAR exert a negative cross-
effect on their reciprocal synthesis and that the AICAR/ATP
balance is crucial for growth. This was confirmed by analyzing a
set of 18 yeast strains (all derived from an ade16 ade17 ade8
his1 background) accumulating various amounts of AICAR
(Fig. 7A, gray dots). We indeed found a strong negative corre-
lation between the concentrations of AICAR and ATP. In par-
ticular,mutants stimulatingAICARuptake (thi3, thi80, or pdc2
(4)) all strongly increased intracellular AICAR while severely
decreasing ATP concentration (Fig. 7A, gray dots) compared
with the ade16 ade17 ade8 his1 control strain (Fig. 7A, black
dot). Because these uptake mutants are not directly connected
to purine metabolism, we conclude that the AICAR-ATP con-
nection is a general phenomenon not restricted to a subset of
specific mutants.
This was further established by studying the ATP/AICAR
balance in the ade16 ade17 ade8 his1 strain supplemented with
various concentrations of AICAr. Once again, we found a
strong inverse connection between the two metabolites
(Fig. 7B).
Finally, we took advantage of a kcs1 knock-out mutant pre-
viously shown to accumulate higher concentrations of ATP
than the wild-type strain (21). The kcs1 knock-out was com-
bined with the ade16 ade17 ade8 his1mutations. As expected,
the kcs1mutation resulted in increased intracellular ATP con-
centration (Fig. 7C), whereas AICAR was not significantly
affected (Fig. 7D). Of note, in this mutant ATP accumulation
does not impact on AICAR concentration because AICAR is
provided from the medium in its riboside form and not from
ATP-repressible de novo pathway. Most importantly, the kcs1
mutation allowed a robust growth in the presence of AICAR,
even though it showed reduced growth in the absence of
AICAR (Fig. 7E).
Together, these results establish that AICAR impacts on the
ATP concentration and that ATP affects AICAr toxicity. We
conclude that disruption of nucleotide homeostasis by AICAR
is critical for its effects on yeast cell proliferation.
AICAR Affects Glucose Utilization and Slows Down Growth
Recovery after Glucose Replenishment—How does AICAR
impact on ATP synthesis? Based on the suppression results, we
reasoned that expression of Apt1 could be affected by AICAR.
Indeed, the Apt1 steady state level was 4–5-fold lower in an
AICAR accumulating strain (Fig. 8A). This could in part be due
to the reduced transcription of APT1 (1.7-fold) found in
microarray experiments comparing an ade16 ade17 strain
accumulating AICAR to an isogenic wild-type strain (4). We
conclude that down-expression of Apt1 in the presence of
AICAR could limit AMP synthesis and contribute to the low
purine nucleotide pools found in the AICAR-accumulating
yeast cells. However, we found that overexpression of APT1
FIGURE 5. ATP and GTP are both limiting for growth of the ade16 ade17 aah1 mutant on adenine. A and B, the ade16 ade17 aah1 (Y8793) strain was
transformedwith plasmids allowing or not allowing (None, pCM189) overexpression of the indicated genes. Transformantswere kept in exponential phase for
24 h in SDcasaWmedium supplementedwith hypoxanthine, harvested by centrifugation, resuspended in SDcasaWAmedium, and grown for 4 h at 30 °C prior
tometabolic extraction and separation. Quantificationswere determined fromat least three independentmetabolite extractions. Error bars indicate variations
to themean.ATPandGTPcontents in cells containing theempty vectorwereusedas referenceandwere set at 1.C, theade16ade17aah1mutant strain (Y8793)
transformed with a plasmid expressing the hCNT3 nucleoside transporter was grown overnight in SDcasaWHypox medium, serial diluted, and spotted on
SDcasaWmedium supplemented with the indicated nucleobase and/or nucleoside used as purine sources.
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could neither fully suppress the AICAR sensitivity of the ade13
mutant nor increase the ability of a wild-type strain to grow in
the presence of AICAR (Fig. 8B).We conclude that Apt1 down-
expression in the presence of AICAR contributes to AICAR
sensitivity but does not account for all of it.
Then the question remains as to how AICAR impacts on
ATP synthesis aside from its effects on the Apt1 steady state
level. One obvious possibility would be that AICAR affects ATP
production fromADP, which in yeastmainly takes place via the
glycolytic pathway when cells are grown on glucose as a carbon
source. Should this be true, such AICAR effects would be lost
on carbon sources that do not require the glycolytic pathway.
To address this issue, we grew the aah1 ade16 ade17 triple
mutant on various carbon sources in the presence of adenine or
hypoxanthine as a purine source. Clearly the triple mutant
could grow on all media containing hypoxanthine as a purine
source (Fig. 9A), although growth was slower on strict respira-
tory media. When adenine was the purine source, the triple
mutant did not grow on glucose or fructose but grew on galac-
tose, lactate, and glycerol/ethanol media (Fig. 9, A and B). This
result thus establishes thatAICARcytotoxicity is stronglymod-
ulated by the carbon source.
Importantly, metabolite profiling of the aah1 ade16 ade17
strain revealed that growth in galactose resulted in higher ATP
and GTP levels, whereas AICAR levels were concomitantly sig-
nificantly reduced (Fig. 9C). Thus, the growth phenotype (Fig.
9A) was once again strictly correlated to the AICAR balance
with ATP and GTP (Fig. 9C). Of note, the UTP pool was
reduced on galactose compared with glucose, possibly because
of utilization of UTP for synthesis of UDP derivatives necessary
for galactose utilization. These data showing that growth on
galactose resulted in a much lower AICAR/ATP and AICAR/
GTP ratios and allowed growth further support our assumption
that the high AICAR/NTP ratio on glucose is detrimental for
growth on this carbon source.
Consistently, we noticed that yeast strains accumulating
AICAR, when shifted from post-diauxic growth conditions to
fresh glucosemedium, required a longer adaptation time before
entry into exponential growth. During this adaptation period,
known as “lag phase,” cell number remains relatively constant
prior to rapid growth. The double ade16 ade17mutant, unable
to metabolize AICAR and thus accumulating it, was compared
with a wild-type strain and to a quadruple ade16 ade17 ade8
his1 mutant that cannot synthesize nor metabolize AICAR.
Clearly, the ade16 ade17 AICAR-accumulating mutant had a
much longer lag phase than the isogenic wild-type strain (Fig.
9D), although its doubling time during exponential growth was
not increased (84 min compared with 89 min for the wild-type
strain). Importantly, the longer lag-phase was not found in
the ade16 ade17 ade8 his1 mutant that does not accumulate
AICAR (Fig. 9D), thereby indicating that AICAR and not the
ade16 ade17blockper se is responsible for this phenotype.Con-
FIGURE 6. AICAR accumulation is highly toxic for cells unable to use
hypoxanthine as an external purine source. A, the diploid strain obtained
by crossingade16ade17 (Y1095) andhpt1 (Y1127) strainswas sporulated, and
spores were separated by micromanipulation on YPDAUW medium. The
ade17 hpt1doublemutant is underlined. Deducedgenotype of lacking spores
corresponding to the unviable triple mutant is shown in bold type. B, cells
were grown overnight, serial diluted, and spotted on SCmedium containing
adenine and lacking ( HIS) or not ( HIS) histidine. Wild type: Y4479; hpt1:
Y5864; ade16: Y5870; ade17: Y5876; ade16 ade17: Y5868 and hpt1 ade17:
Y5873. C, cells (hpt1 ade17: Y5873) were transformed with the APT1 express-
ing plasmid (P2091) or the empty vector (pCM189). Transformants were
grown overnight, serial diluted, and spotted on SC medium containing ade-
nine and lacking (HIS) or not (HIS) histidine.D, transformants fromCwere
kept in exponential growth for 24 h in SC-U medium supplemented with
histidine, harvested by centrifugation, resuspended in SC-U medium lacking
histidine, and grown for 4 h at 30 °C prior tometabolic extraction. Quantifica-
tions were determined from at least three independent metabolite extrac-
tions, and the standard deviations are presented. Metabolite content of cells
not overexpressing APT1were used as reference and set at 1. E, mutant cells
(ade16 ade17 ade8 his1 (Y6986); ahs15 ade16 ade17 ade8 his1 (Y7320)) were
grown overnight, serial diluted, and spotted on SDCasaWUmedium supple-
mented with either adenine or hypoxanthine and with or without external
AICAr (5mM). The plateswere imaged after 2 days at 30 °C. F, cells fromFig. 6E
were kept in exponential growth for 24 h in SDCasaWU medium and sub-
jected tometabolic extraction.Quantificationsweredetermined fromat least
three independent metabolite extractions, and standard deviations are pre-
sented.Metabolite content in the ADE13 cells was used as a reference and set
at 1.
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sistently, the lag-phase of the ade16 ade17 mutant was short-
ened when these cells carried a plasmid expressing the Pho13-1
phosphatase that leads to decreased intracellular concentration
of AICAR (9) (Fig. 9E). These results indicate that AICAR accu-
mulation affects the capacity of yeast cells to adapt to the new
glucose rich medium and initiate exponential growth.
All together these results reveal glucose utilization as an
important basis of AICAR toxicity in yeast. We then asked
whether this could also be the case in human cells.
Growth on Galactose Allows to Bypass AICAR Toxicity in
Human Cells—We investigated the effect of AICAr on human
HeLa cells propagated in glucose and galactose-containing
medium. HeLa cells grown on galactose exhibited a lower
mitotic index than in the presence of glucose (doubling times
60 h versus 24 h, respectively) (Fig. 10,A and B), as previously
FIGURE 7. AICAR/ATP balance is critical for AICAR toxicity. A, strains were kept in exponential growth for 24 h in SDcasaWAUmedium at 30 °C and shifted
at 37 °C for 30min, and AICAr (1.72mM) was added for 1 h prior tometabolite extraction. The ade16 ade17 ade8 his1 (Y6986) control is shown in black, and the
thi3ade16ade17ade8his1 (Y7321), thi80ade16ade17ade8his1 (Y8845), andpdc2ade16ade17ade8his1 (Y7314) strains are indicated. Theothermutants shown
in gray correspond to unidentified AICAr-sensitive mutants. Quantifications were done on at least three independent metabolite extractions, and error bars
indicatevariation to themean.AICARandATPcontentsof thecontrol strain (blackdot)were set at 1.B, theade16ade17ade8his1mutant strain (Y2950)waskept
in exponential phase for 24 h in SDcasaWAUmedium containing the indicated concentrations of external AICAr prior tometabolite extraction and separation
by liquid chromatography. AICAR (light gray dots) and ATP (dark gray dots) content was set at 1 for cells grown in medium containing either 1 mM or 0 mM of
AICAr, respectively. C and D, ATP and AICAR content were determined on cells (ade16 ade17 ade8 his1 (Y2950; light gray bars); kcs1 ade16 ade17 ade8 his1
(Y10399, dark gray bars)) exponentially grown for 24 h in SDcasaWAUmediumwith () or without () AICAr (1 mM). ATP (C) and AICAR (D) contents were set
at 1 for KCS1 cells grown in the presence of AICAr. E, mutant cells (ade16 ade17 ade8 his1 (Y2950); kcs1 ade16 ade17 ade8 his1 (Y10399)) were grown overnight,
serial diluted, and spotted on SDcasaWAUmediumwith orwithout external AICAr at the indicated concentration. The plateswere imaged after 2 days at 30 °C.
FIGURE 8. The adenine phosphoribosyl transferase steady state level is
affected by AICAR. A, total protein extracts from cells that accumulated
AICAR (ade16 ade17 APT1-GFP, Y10351) or that did not accumulate AICAR
(APT1-GFP, Y10314) were separated by SDS-PAGE, and Apt1-Gfp (anti-GFP,
Roche catalog no. 11814460001 dilution 1/1,000) and Act1 (anti-Act1, gener-
ous gift from I. Sagot (Bordeaux, France); 1/100,000) were detected by West-
ernblotting.B, strains (ade16ade17ade8his1 (ADE13; Y6986) andade16ade17
ade8 his1 ade13 (G166S) (ade13; Y7320) were transformed with the APT1
expressing plasmid (P2091) or the cognate empty vector (pCM189). Transfor-
mants were grown overnight, serial diluted, and spotted on SDcasaWA
medium containing AICAr.
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reported by others (22). AICAr seriously impaired the ability of
HeLa cells to grow in the presence of glucose in a dose-depen-
dent manner (Fig. 10A). In comparison, no significant inhibi-
tion of growthwas obtained under AICAr treatment when sub-
stituting glucose with galactose (Fig. 10B). Indeed, the
proliferation ofHeLa cells was unaffected at higher doses (1 and
3 mM) of AICAr in the presence of galactose, whereas it was
almost completely inhibited when using the glucose medium
(Fig. 10, A and B). Comparison of metabolite profiles of HeLa
cells grown on glucose and galactose revealed lower AICAR
levels in cells grown in galactose compared with glucose (Fig.
10,C andD). In the absence of AICAR, cells grown in galactose
accumulatedmore of all fourNTPs (Fig. 10,E–L). AICAR treat-
ment resulted in an increased amount of purine nucleotides
and a severe drop of pyrimidine triphosphate pools (Fig. 10,
E–L). This effect was strongly reduced in cells grown on galac-
tose compared with glucose, suggesting that it could at least in
part account for AICAR toxicity. The differential effects of
AICAr on proliferation depending on the carbon source could
not be simply attributed to differences in AICAR nor pyrimi-
dine nucleotide contents. Indeed, AICAR accumulation was
analogous in glucose  1 mM AICAr and galactose  3 mM
AICAr (Fig. 10, C andD), whereas pyrimidine nucleotide pools
(Fig. 10, I–L) and proliferation (Fig. 10, A and B) were clearly
FIGURE 9. AICAR affects ATP synthesis via alteration of glucose utilization. A, cells (aah1 ade16 ade17; Y8793) were grown overnight, serial diluted, and
spotted on SDcasaWU medium containing the indicated carbon source (2% w/v) and either adenine or hypoxanthine. The plates were imaged after 2 days
(glucose, fructose, and galactose panels) or 3 days (lactate and glycerol ethanol) at 30 °C. B, schematic representation of carbon source utilization in yeast.
Hxk, hexokinase; Pfk, phosphofructokinase. C, cells (aah1 ade16 ade17; Y8793) were kept in the exponential growth phase for 24 h in ScasaWHypox containing
either 2% glucose or 2% galactose as carbon source. The cells were then harvested by centrifugation, resuspended in the same two media but containing
adenine instead of hypoxanthine, and grown for 4 h at 30 °C prior to metabolic extraction. Quantifications were determined from at least five independent
metabolite extractions, and the standard deviation is indicated. D, cells grown for 48 h in SDcasaWAmedium were then diluted in fresh SDcasaWAmedium,
and cell growthwas followed for 6h at 30 °Cusing aMultisizer IV (BeckmanCoulter).WT: Y4479;ade16ade17: Y6681 andade16ade17ade8his1: Y6986. E, AICAR
accumulation is required for the lagphasedelay of theade16ade17mutant.WTandade16ade17mutant strainswere transformedwith theplasmid expressing
PHO13-1 (P4291) or the empty vector (pCM189).
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differently affected. In addition, at lower AICAr concentration
(0.3 mM) on glucose, pyrimidine nucleotides were severely
reduced (Fig. 10, I–K), whereas proliferation was only slightly
affected (Fig. 10A). However, by combining both parameters
and considering the AICAR/(UTPCTP) ratio, a strong nega-
tive correlation between this ratio and proliferation is found
(Fig. 10, A and B, ratios are shown in parentheses).
Discussion
This work addressed the toxicity of AICAR in eukaryotic
cells. AICAR is known to disturb cellular functions through its
well established AMP-mimetic properties and in particular
through its activating effect on AMPK. However, a growing
number of reports have established that the cellular effects of
AICAR, initially thought to be mainly due to activation of
AMPK, are proving to be much more complicated (1, 2). In
particular, the recent demonstration that the antiproliferative
effects of AICAR areAMPK-independent (5, 6) has stressed the
necessity to identify new functions affected by AICAR.
AICAR Strongly Interferes with NTPs Metabolism—Our
search for AICAR-synthetically lethal mutants revealed that
adenine deaminase (Aah1) is critical for yeast cells to maintain
adequate ATP levels when adenine is provided as a purine
source andwhenAICAR accumulates. Our previous work indi-
cated that the adenine deaminase route is the major adenine
utilization route in yeast (23), and accordingly we found that
aah1 mutants accumulate much more adenine than the apt1
mutant (Fig. 2C). In the course of this work, we observed that
adenine accumulation was associated to accumulation of
AdoMet and SAH and that this effect was AICAR-independent
(Figs. 2 and 4). We propose that accumulation of AdoMet and
SAH could be due to in vivo inhibition of SAH hydrolase by
adenine because such an inhibition had been reported to occur
in vitro (24). However, our data do not support a role for
AdoMet and SAH accumulation in the AICAR synthetically
lethal phenotype.
In the aah1mutant, AICAR accumulation was associated to
a lower ATP and GTP concentration. Because ATP exerts an
allosteric negative regulation on the purine pathway, lowering
ATP results in increased concentration of AICAR as previously
described (25). The decreased ATP and GTP levels would in
part be due to the aah1mutation restraining AMP synthesis to
the Apt1 route. This phenomenonwas found to be amplified by
low expression of Apt1 when AICAR accumulates. Consis-
tently, overexpression of Apt1 allowed replenishing the ATP
and GTP pools. However, because the NTP pools were not
affected in the aah1 single mutant grown with adenine, it is
clear that AICAR accumulation, resulting from the ade16
ade17 knock-out, contributes to lowering ATP and GTP levels
(see “AICAR Affects Glucose Utilization in Vivo”). Under con-
ditions restoring growth (hypoxanthine or overexpression of
APT1), AICAR decreased and ATP GTP increased, suggest-
ing that the AICAR/(ATPGTP) balance is crucial for AICAR
toxicity.
Importantly, the effect of AICAR on nucleotide homeostasis,
initially observed in the aah1mutant, was not restricted to this
particular genetic background because it was also found in
other mutants (hpt1 and ade13). In addition, in a nonmutant
FIGURE 10.Human cells grown in galactose instead of glucose are signif-
icantly more resistant to AICAr. A and B, HeLa cells were seeded in 24-well
plates in media containing 5 mM of either glucose (A) or galactose (B) and
allowed to settle for 24 h. AICAr was then added (day 0) at the indicated
concentrations, and cells were numerated each day. The results aremeans of
triplicate experiments, and the error bars represent standard deviation. The
values in parentheses correspond to the intracellular ratios [AICAR]/
([CTP][UTP]) at day 2. C–L, intracellular contents of AICAR and of NTPs (ATP,
GTP,UTP, andCTP) at day 2 as a functionof external AICAr concentrations and
carbon sources.
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background, we could establish that AICAR strongly affected
ATP concentration (Fig. 7B). Conversely, using the kcs1
mutant, we could show that an increase of the ATP pool was
sufficient to alleviate AICAR toxicity (Fig. 7, C–E). Together,
our results establish that AICAR balance with nucleotides
triphosphate is a critical factor contributing to its toxicity.
Our data establish that AICAR accumulation is synthetically
lethal with the hpt1 knock-out abolishing hypoxanthine-gua-
nine phosphoribosyltransferase activity. Strikingly, AICAR is
accumulated in body fluids of patients suffering purine metab-
olism diseases, including hypoxanthine-guanine phosphoribo-
syltransferase-deficient patients (15, 26). It should be stressed
that the levels of AICAR accumulated by these patients (15) are
way below those resulting in synthetic lethality in yeast cells
(this work). However, should AICAR have similar effects in
human cells than the ones observed in yeast, it could contribute
to the phenotypic outcome of these complex developmental
genetic diseases. Accordingly, we recently found that, in addi-
tion to AICAR accumulation, NTP levels were significantly
lower in erythrocytes from a large cohort of hypoxanthine-gua-
nine phosphoribosyltransferase-deficient patients (15).
AICAR Affects Glucose Utilization in Vivo—As mentioned
previously, our results show that AICAR and ATP negatively
impact on their reciprocal synthesis. The control exerted by
ATP on AICAR synthesis is likely due to the fact that AICAR
synthesis is modulated through feedback inhibition of the first
step of the purine de novo pathway by ATP (25). How then does
AICAR impact on ATP synthesis?
We found that AICAR quite specifically affects growth on
glucose as a carbon source. Growth on fructose is also affected,
but utilization of both carbon sources relies on hexokinase
activity for the first step of glycolysis. Meanwhile, AICAR is far
less toxic on galactose, which allows bypassing the hexokinase
step and feeding the glycolytic pathway with glucose-6-phos-
phate (Fig. 9B). Importantly, this carbon source specific effect
was found in both yeast and human cells, suggesting a possibly
conserved mechanism of AICAR on glucose utilization, even
though in mammalian cells AICARmostly affected pyrimidine
triphosphate nucleotides. The underlying mechanism leading
to this difference between yeast and mammalian cells remains
to be explored. In vitro inhibitory effects ofAICARon glycolysis
have been documented on mammalian enzymes (27, 28), but
the in vivo consequences had not been evaluated. Suppression
of AICAR toxicity by galactose, but not by fructose, points to
glucose-6-phosphate synthesis as a major step affected by
AICAR. In hepatocytes, AICARmoderately affects glucokinase
enzymatically (28) and inhibits glucokinase translocation (29).
In yeast, we could not find any inhibitory effect of AICAR on
glucose phosphorylation in vitro.5 In tumor cells, the basis of
AICAR effects on glucose utilization is to be established.What-
soever the exactmechanism(s) involved in vivo, ourwork estab-
lished that AICAR inhibition of glucose utilization can signifi-
cantly contribute to its antiproliferative properties. AICAR
effects on glucose utilization are likely to affect more specifi-
cally tumor cells that strictly rely on the glycolytic pathway
because of the Warburg effect.
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